• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock.

作者信息

Itzhaki Ben Zadok Osnat, Ben-Avraham Ben, Nohria Anju, Orvin Katia, Nassar Mithal, Iakobishvili Zaza, Neiman Victoria, Goldvaser Hadar, Kornowski Ran, Ben Gal Tuvia

机构信息

Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel.

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

JACC CardioOncol. 2019 Sep 24;1(1):141-144. doi: 10.1016/j.jaccao.2019.07.004. eCollection 2019 Sep.

DOI:10.1016/j.jaccao.2019.07.004
PMID:34396174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8352193/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e7e/8352193/f1d0ad0593d6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e7e/8352193/f1d0ad0593d6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e7e/8352193/f1d0ad0593d6/gr1.jpg

相似文献

1
Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock.免疫检查点抑制剂诱发的暴发性心肌炎和心源性休克。
JACC CardioOncol. 2019 Sep 24;1(1):141-144. doi: 10.1016/j.jaccao.2019.07.004. eCollection 2019 Sep.
2
Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support.在VA-ECMO支持下暴发性免疫检查点抑制剂相关心肌炎的延迟诊断与恢复
JACC CardioOncol. 2022 Dec 20;4(5):722-726. doi: 10.1016/j.jaccao.2022.08.013. eCollection 2022 Dec.
3
A Novel Treatment for a Rare Cause of Cardiogenic Shock.一种针对心源性休克罕见病因的新型治疗方法。
JACC Case Rep. 2020 Apr 22;2(10):1461-1465. doi: 10.1016/j.jaccas.2020.02.004. eCollection 2020 Aug.
4
Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients.原位心脏移植受者中的免疫检查点抑制剂相关性心肌炎和细胞排斥反应
JACC CardioOncol. 2022 Dec 20;4(5):717-721. doi: 10.1016/j.jaccao.2022.07.013. eCollection 2022 Dec.
5
Influenza A (H3N2) Induced Fulminant Myocarditis Requiring Mechanical Circulatory Support.甲型流感（H3N2）诱发的暴发性心肌炎需机械循环支持
JACC Case Rep. 2019 Aug 21;1(2):133-137. doi: 10.1016/j.jaccas.2019.06.006. eCollection 2019 Aug.
6
V-A ECMO for neonatal coxsackievirus B fulminant myocarditis: a case report and literature review.新生儿B组柯萨奇病毒暴发性心肌炎的静脉-动脉体外膜肺氧合治疗：一例报告及文献综述
Front Cardiovasc Med. 2024 May 21;11:1364289. doi: 10.3389/fcvm.2024.1364289. eCollection 2024.
7
Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study.心肌肌钙蛋白 T 和 NT-proBNP 作为系统性硬化症原发性心脏受累和疾病严重程度的诊断和预后生物标志物：一项前瞻性研究。
Eur J Intern Med. 2019 Feb;60:46-53. doi: 10.1016/j.ejim.2018.10.013. Epub 2018 Oct 23.
8
Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.联合使用高敏心肌肌钙蛋白 T 和 N 末端脑利钠肽前体可改善慢性心力衰竭患者的预后，优于传统的死亡风险因素。
Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.
9
Factors Associated With In-hospital Mortality of Children With Acute Fulminant Myocarditis on Extracorporeal Membrane Oxygenation.体外膜肺氧合支持下急性暴发性心肌炎患儿院内死亡的相关因素
Front Pediatr. 2020 Aug 27;8:488. doi: 10.3389/fped.2020.00488. eCollection 2020.
10
The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure.沙库巴曲缬沙坦对慢性心力衰竭患者临床治疗、高敏肌钙蛋白T（hs-cTnT）及N末端B型利钠肽原（NT-ProBNP）血清水平和左心室功能的影响
Int Heart J. 2020 Jan 31;61(1):1-6. doi: 10.1536/ihj.19-231. Epub 2019 Dec 26.

引用本文的文献

1
Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review.类固醇难治性免疫检查点抑制剂相关心肌炎的治疗药物：一项叙述性综述
Cardiovasc Diagn Ther. 2024 Aug 31;14(4):679-697. doi: 10.21037/cdt-24-114. Epub 2024 Aug 12.
2
Treatment of Immune Checkpoint Inhibitor-associated Myocarditis.免疫检查点抑制剂相关性心肌炎的治疗。
J Cardiovasc Pharmacol. 2024 May 1;83(5):384-391. doi: 10.1097/FJC.0000000000001456.
3
Drug therapy for myocarditis induced by immune checkpoint inhibitors.免疫检查点抑制剂所致心肌炎的药物治疗

本文引用的文献

1
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.阿巴西普用于治疗严重的免疫检查点抑制剂相关心肌炎
N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677.
2
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.阿仑单抗治疗因PD-1治疗引起的免疫相关性心肌炎。
N Engl J Med. 2019 Jun 13;380(24):2375-2376. doi: 10.1056/NEJMc1903064.
3
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.免疫检查点抑制剂治疗与心肌炎：已报告病例的系统综述。
Front Pharmacol. 2023 May 25;14:1161243. doi: 10.3389/fphar.2023.1161243. eCollection 2023.
4
Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases.免疫检查点抑制剂相关心肌炎：已报道临床病例综述
Diagnostics (Basel). 2023 Mar 25;13(7):1243. doi: 10.3390/diagnostics13071243.
5
Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support.在VA-ECMO支持下暴发性免疫检查点抑制剂相关心肌炎的延迟诊断与恢复
JACC CardioOncol. 2022 Dec 20;4(5):722-726. doi: 10.1016/j.jaccao.2022.08.013. eCollection 2022 Dec.
6
Brazilian Society of Cardiology Guideline on Myocarditis - 2022.巴西心脏病学会心肌炎指南 - 2022年
Arq Bras Cardiol. 2022 Jul;119(1):143-211. doi: 10.36660/abc.20220412.
7
Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.癌症患者中免疫检查点抑制剂诱导的心肌炎：一例病例报告及已报道病例综述
Cardiooncology. 2021 Aug 9;7(1):27. doi: 10.1186/s40959-021-00114-x.
8
Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management.免疫检查点抑制剂相关心肌炎：诊断和管理中的实用考虑。
Anatol J Cardiol. 2020 Aug;24(2):68-75. doi: 10.14744/AnatolJCardiol.2020.79584.
9
Preventive Cardio-Oncology: The Time Has Come.预防性心脏肿瘤学：时机已至。
Front Cardiovasc Med. 2020 Jan 10;6:187. doi: 10.3389/fcvm.2019.00187. eCollection 2019.
J Cancer Res Clin Oncol. 2019 Jun;145(6):1527-1557. doi: 10.1007/s00432-019-02927-x. Epub 2019 Apr 26.
4
Cardiovascular toxicities associated with immune checkpoint inhibitors.免疫检查点抑制剂相关的心血管毒性。
Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026.
5
Immune checkpoint inhibitors and cardiovascular toxicity.免疫检查点抑制剂与心血管毒性。
Lancet Oncol. 2018 Sep;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1.
6
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者的心肌炎。
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.
7
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
8
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.免疫检查点抑制剂相关心脏毒性的临床特征、管理及结局
Circulation. 2017 Nov 21;136(21):2085-2087. doi: 10.1161/CIRCULATIONAHA.117.030571.
9
Cardiovascular Toxicities Associated with Cancer Immunotherapies.与癌症免疫疗法相关的心血管毒性
Curr Cardiol Rep. 2017 Mar;19(3):21. doi: 10.1007/s11886-017-0835-0.
10
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.免疫检查点抑制剂相关不良反应的治疗：综述。
JAMA Oncol. 2016 Oct 1;2(10):1346-1353. doi: 10.1001/jamaoncol.2016.1051.